NEW YORK, NY / ACCESSWIRE / March 1, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Bright Health Group, Inc. (NYSE:BHG)
This lawsuit is on behalf of all persons and entities other than defendants that purchased or otherwise acquired: (a) Bright Health common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about June 24, 2021; and/or (b) Bright Health securities between June 24, 2021 and November 10, 2021.
Lead Plaintiff Deadline: March 7, 2022
Throughout the class period, Bright Health Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Bright Health had overstated its post-IPO business and financial prospects; (ii) the Company was ill-equipped to handle the impact of COVID-19-related costs; (iii) the Company was experiencing a decline in premium revenue because of a failure to capture risk adjustment on newly added lives; (iv) all the foregoing was reasonably likely to have a material negative impact on Bright Health’s business and financial condition; and (v) as a result, the documents issued in connection with the IPO and Defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Learn about your recoverable losses in BHG: https://www.kleinstocklaw.com/pslra-1/bright-health-group-inc-loss-submission-form?id=24180&from=1
Talkspace, Inc. f/k/a Hudson Executive Investment Corporation (NASDAQ:TALK)
This lawsuit is on behalf of: (a) all persons or entities that purchased or otherwise acquired Talkspace securities between June 11, 2020 and November 15, 2021, both dates inclusive, and/or (b) all holders of Talkspace common stock as of the record date for the special meeting of shareholders held on June 17, 2021.
Lead Plaintiff Deadline: March 8, 2022
During the class period, Talkspace, Inc. f/k/a Hudson Executive Investment Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Hudson Executive Investment Corporation (“HEIC”) had overstated its competitive advantage and due diligence capabilities with respect to identifying and effectuating a merger with target companies; (ii) HEIC had conducted inadequate due diligence into then-private, pre-Merger Talkspace, or else ignored and/or failed to disclose multiple red flags concerning then-private, pre-Merger Talkspace’s business and operations; (iii) Talkspace was experiencing significantly increased online advertising costs in its B2C business since the beginning of 2021; (iv) Talkspace was experiencing lower conversion rates in its online advertising in its business-to-consumer (“B2C”) business; (v) as a result of (iii) and (iv) above, Talkspace was experiencing increased customer acquisition costs and more tepid B2C demand than represented to investors; (vi) as a result of (iii)-(v) above, Talkspace was suffering from ballooning customer acquisition costs and worsening growth and gross margin trends; (vii) Talkspace had overvalued its accounts receivables from certain of its health plan clients in its B2B business, which amounts required adjustment downward; and (viii) as a result of (iii)-(vii) above, Talkspace’s 2021 financial guidance was not achievable and lacked any reasonable basis in fact.
Learn about your recoverable losses in TALK: https://www.kleinstocklaw.com/pslra-1/talkspace-inc-f-k-a-hudson-executive-investment-corporation-loss-submission-form?id=24180&from=1
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
The complaint alleges that during the class period Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in FENC: https://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?id=24180&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE : The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/690947/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BHG-TALK-and-FENC